MMV183

Product vision
  • Uncomplicated malaria treatment and resistance management
  • Potential for use in severe malaria
MoA
  • Inhibition of acetylCoA synthetase (acetylCS)
  • No pre-existing resistance, no resistance in vitro
Key features
  • Novel mechanism of action
  • Predicted human efficacious dose = 100 mg single dose
  • High solubility and good overall physical properties
  • Transmission-blocking activity
Challenges
  • Challenge to define safety margins, as exposure decreases strongly after the second dose in all preclinical tests
Status
  • Preclinical development
Next milestone
  • Conduct Good Laboratory Practice (GLP) toxicology and safety pharmacology programme
  • Optimization of synthesis route and formulation
Previously
  • From a discovery collaboration with TropIQ
MMV Project Director
  • Ilaria Di Resta